Life Sciences

GSK joins disclosure parade

Pharma Compliance Alert, October 29, 2008

The list of pharmaceutical companies that will disclose payments to physicians is getting longer.

GlaxoSmithKline (GSK) plans to disclose how much funding it provides to physicians and medical schools, according to a Financial Times article. GSK will also cap payments to U.S. physicians at $150,000 per year.

The planed disclosure is not the first for GSK. In August, the company unveiled plans to post its educational and charitable grants quarterly beginning in February 2009.

Other pharmaceutical companies will also reveal payments to physicians. Eli Lilly announced in September that it would begin disclosing all payments over $500 to physicians when it launches a publicly-accessible online registry of physician payments in the second half of 2009.

Merck followed with its plans to disclose payments to physicians who serve as speakers for the company in 2009. Merck previously announced it would begin disclosing grants to patient organizations, medical professional societies, and other organizations beginning this month.

Johnson & Johnson will begin disclosing educational grants and grants to patient-advocacy organizations in 2009, while AstraZeneca already posts contributions to non-profit organizations and educational grants.

Comments

0 comments on “GSK joins disclosure parade